Key Highlights

  • Loss per share was USD 0.79 against an estimate of a USD 0.76 loss.
  • Net loss was USD 47.97 million, against USD 30.09 million a year earlier.
  • Research and development expenses were USD 40.22 million, against USD 25.19 million.
  • Cash and marketable securities were USD 477.0 million at September 30.

Maze Therapeutics (NASDAQ:MAZE) reported a third quarter 2026 loss per share of USD 0.79, against an estimate of a USD 0.76 loss and a USD 0.66 loss in the third quarter of 2025. Net loss was USD 47.97 million, compared with USD 30.09 million.

The loss from operations was USD 51.52 million, compared with USD 32.97 million a year earlier. The company reported the figures in its quarterly filing for the period ended September 30, 2026.

Operating Expenses and Net Loss

Research and development expenses were USD 40.22 million, compared with USD 25.19 million. General and administrative expenses were USD 11.30 million, compared with USD 7.78 million. Total operating expenses were USD 51.52 million, against USD 32.97 million.

The filing reports share-based compensation within Research and Development expenses of USD 4.80 million, compared with USD 2.43 million, and within general and administrative expenses of USD 3.75 million, compared with USD 1.44 million. Other income, net, primarily consists of interest income earned on cash, cash equivalents and marketable securities, and interest expense recognized on the Loan and security agreement with Hercules Capital, Inc. and certain lenders.

Nine-Month Results

For the nine months ended September 30, 2026, net loss was USD 116.90 million, compared with USD 96.55 million, and the loss per share was USD 2.02, against USD 2.45. Total operating expenses were USD 146.11 million, against USD 104.84 million.

Research and development expenses for the nine months were USD 109.31 million, against USD 80.88 million, and general and administrative expenses were USD 36.80 million, against USD 23.96 million.

Cash Position and Licensing Agreements

As of September 30, 2026, the company had cash, cash equivalents and marketable securities of USD 477.0 million. Cash and cash equivalents were USD 154.16 million, compared with USD 189.25 million at the prior Balance Sheet date, and current marketable securities were USD 235.50 million, compared with USD 152.67 million.

The filing describes two license agreements entered into in March 2024. Under the Trace License Agreement, the company granted Trace Neuroscience, Inc. an exclusive worldwide license to a discovery research program targeting UNC13A for the treatment of amyotrophic lateral sclerosis, and received an upfront payment of USD 15.0 million in April 2024. Under the Shionogi License Agreement, the company granted Shionogi & Co., Ltd. an exclusive, worldwide, sublicensable license to research, develop, manufacture and commercialize MZE001 and certain other small molecule compounds.

The filing also describes the 2025 Employee Stock Purchase Plan, which the Board of Directors and stockholders approved and which became effective on January 30, 2025. The company identifies itself as a clinical-stage biopharmaceutical company with a limited operating history.

Maze Therapeutics Q3 2026 Earnings: Key Takeaways

Maze Therapeutics reported a third quarter 2026 loss per share of USD 0.79 and a net loss of USD 47.97 million. Research and development expenses were USD 40.22 million, and cash, cash equivalents and marketable securities were USD 477.0 million.